Lung Cancer Clinical Trial
Official title:
Pleural Ultrasonography in Lung Cancer - PULC
Lung cancer remains the leading cause of mortality from malignant diseases in both men and
women worldwide. Accurate diagnosis, staging and therapeutic targeting of lung cancer and
other pulmonary pathology are vital with regards to providing patients with expedient and
accurate treatment and treatment plans. The pre-operative evaluation and consultation in
patients who are to undergo operative staging or resection for lung cancer is
multidimensional and involves detailed history taking, physical examination and review of
imaging studies. Two important elements of both staging and pre-operative evaluation include
the evaluation of: (1) the pleural space for malignant pleural effusion and (2) the
diaphragm for appropriate movement. At this point in time, the pleural space evaluation is
being performed using CT scan which does not allow the acquisition of real-time cytological
material from pleural effusions due to the fact that the CT scans are done in a diagnostic
setting. Diaphragmatic movement/excursion is not currently being assessed pre-operatively
and its impact on staging and post-operative pulmonary function is unknown.
Malignant pleural effusion is recognized as a poor prognosticator in non-small cell lung
cancer patients and has recently been upgraded from a T4 to an M1a status in the new edition
of the AJCC NSCLC Staging System (7th Edition). The appreciation of the poor prognosis
related to malignant effusion has upgraded the stage from a Stage IIIb to a stage IV.
Recognizing the stage early allows for more precise prognostication of disease and can lead
to precision and streamlining of treatment plans for thoracic surgeons and oncologists.
Hypotheses:
1. Pleural ultrasonography with evaluation, quantification and aspiration of pleural
effusion allows for improved pre-operative staging and alters decision-making patterns
for lung cancer patients.
2. Pleural ultrasonography with evaluation of appropriate diaphragmatic respiratory
movement can predict post-operative complications in patient undergoing lung cancer
surgery.
Objectives:
The goals of this project within the program are to:
1. Evaluate the improvement in pre-operative staging with the addition of pre-operative
pleural ultrasonography for malignant pleural effusion.
2. Evaluate the ability of pre-operative diaphragmatic ultrasound to predict
post-operative morbidity following pulmonary surgery.
Methodology:
This study will consist of a prospective evaluation of surgeon-performed pleural and
diaphragmatic ultrasound in the pre-operative evaluation of lung cancer patients. All
patients being seen in the thoracic surgery pre-operative clinic with the new or presumed
diagnosis of lung cancer will be approached for prospective enrolment into the study.
Consented patients will undergo standard history and physical examination by the treating
thoracic surgeon. During or after the physical examination, PULC will be performed by the
study investigators.
Measurements will include: (1) bilateral diaphragmatic excursion during sniffing, (2)
pleural fluid evaluation in bilateral costophrenic sulci. Should pleural fluid be found on
the ipsilateral side to the mass (tumor), the fluid will be aspirated under sterile
conditions in the clinic and sent for cytology analysis. US evaluation will be performed in
the upright, supine and decubitus position.
Results will be analyzed using parametric methodology in order to ascertain the additional
information gained and the change in staging (upstaging) with the addition of PULC to
standard history and physical examination during the initial evaluation of thoracic surgical
patients.
The study will enrol 50 patients. Recruitment will occur at the thoracic outpatient surgical
clinic at the CHUM. Enrolment is expected at a level of five patients per week and therefore
the study recruitment is expected to take 2.5 months.
Impact:
The potential impact of a positive trial will change the way clinicians evaluate, stage and
risk stratify patients who are to undergo operative interventions for lung cancer.
;
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03918538 -
A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors
|
N/A | |
| Recruiting |
NCT05078918 -
Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors
|
N/A | |
| Active, not recruiting |
NCT04548830 -
Safety of Lung Cryobiopsy in People With Cancer
|
Phase 2 | |
| Completed |
NCT04633850 -
Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
|
||
| Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT05583916 -
Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery
|
N/A | |
| Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
| Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
| Recruiting |
NCT05898594 -
Lung Cancer Screening in High-risk Black Women
|
N/A | |
| Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
| Active, not recruiting |
NCT03575793 -
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
| Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
| Terminated |
NCT03275688 -
NanoSpectrometer Biomarker Discovery and Confirmation Study
|
||
| Not yet recruiting |
NCT04931420 -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
|
Phase 2 | |
| Recruiting |
NCT06052449 -
Assessing Social Determinants of Health to Increase Cancer Screening
|
N/A | |
| Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
| Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
| Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|